3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
selpercatinib
2
alectinib
2
tucatinib
1
trametinib
1
pamiparib
1
glutathione pegylated liposomal doxorubicin
1
entrectinib
1
elacestrant
1
dabrafenib
1
cobimetinib
1
capmatinib
1
abemaciclib
1
Vemurafenib
1
Trastuzumab
1
Radiation
1
RAD1901
1
Pemetrexed
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
elacestrant
×
CNS
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled